Kornimate/medical-research-clean huggingface dataset:
measuring deep and superficial multifidus and the activation pattern during dynamic task correlating with trunk stability ability and functional performance in different ages asymptomatic and unspecific low back pain adult

Conditions: Low Back Pain

Summary: the first propose of the study is to understand the contraction of deep and superficial multifidus in patients with non-specific low back pain and the elderly. the second purpose of the study is to understand the relationship between the multifidus and the functional performance in patients with non-specific low back pain and the elderly. the hypothesis is that the patients with non-specific low back pain and the elderly have less ability to contract the deep multifidus then asymptomatic adults and younger adults. besides, the multifidus is correlated to the functional performance.


Eligibility criteria:
inclusion criteria: * age 20-90 * have lumbar region discomfort in the past three months, and the discomfort is more than one day * have diagnosis of non-specific low back pain exclusion criteria: * have received surgery of lumbar or lower extremities * neurological symptom (eg. numbness of lower extremities) * have no ability to stand and walking independently * cancer * systemic disease (eg. ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus) * pregnancy
oral propanolol for surgically inaccessible cavernous malformations

Conditions: Cavernous Malformations,Cerebral and/or Spinal

Summary: the purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.

patients between the ages of 1 and 80 years of age, that have been diagnosed with a spinal or cerebral cavernous malformation(s) that can not be surgically treated, will be enrolled in this randomized study. all eligible patients will be enrolled in one of two groups. group 1 will receive oral propranolol tablets 3 times a day for 36 months. group 2 will receive oral placebo tablets 3 times per day for 36 months. prior to beginning treatment, all imaging, including mris, will be evaluated. during the first visit a blood sample will be collected for genomic analysis. patients will return to clinic every 6 months. each time the patient returns to clinic monitoring of how the patient is feeling and evaluation of how the patient is tolerating the propranolol will take place. at the end of the three years, evaluators will determine if the propranolol was able to stop the growth of the cavernous malformation and change the imaging features of the lesion on mri. once the study is completed patients will no longer receive the study drug.

Eligibility criteria:
inclusion criteria: 1. diagnosis of isolated or familial cavernous malformation syndrome: * symptomatic cavernous malformation not amenable to surgical resection. * familial cavernous malformation with seizure, other neurological symptom or surgically inaccessible lesion. 2. written and informed consent obtained prior to study enrollment. 3. subject is able and willing to return for outpatient visits. 4. negative pregnancy test at time of enrollment for women and child-bearing potential. exclusion criteria: 1. age less than 1 year-old. 2. propranolol allergy or allergy to other b-blockers. 3. estimated life expectancy of less than 1 year. 4. history of severe anemia, cardiac dysfunction, or diabetes. 5. a psychiatric or substance abuse problem that may interfere with study compliance. 6. pregnant and lactating women.
left ventricular function after primary percutaneous coronary intervention: role of speckle echocardiography

Conditions: Myocardial Infarction; Echocardiography 2D; Left Ventricular Dysfunction

Summary: recovery of the left ventricular function is variable from one patient to another, thus assessment of cardiac function by measuring left ventricular ejection fraction using echocardiography is the most common in the daily clinical practice. however, this technique has limitation related with its intra- and interobserver variability. a recent technique, 2d speckle tracking for assessing global longitudinal strain, has been introduced to reduce the variability and potentially has a higher accuracy. speckle tracking is a method which uses two dimensions recording for measuring quantity of movement of myocardium in several segments. speckle-tracking echocardiography is a current noninvasive ultrasound imaging technique that allows for an objective and quantitative evaluation of global and regional myocardial function independently from the angle of insonation and from cardiac translational movements,

authors using 2d speckle tracking found that subclinical lv systolic dysfunction is common in patients with isolated severe mitral stenosis (ms) and is determined primarily by the hemodynamic variables of ms severity and reduced lv filling. bmv results in rapid recovery of lv systolic function in these patients through improvement in lv diastolic loading. these findings suggest that lv contractile properties in ms are modulated predominantly by lv diastolic filling rather than myocardial structural abnormality.

Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction eligible for pci seen on admission and after 40 days exclusion criteria: * cardiomyopathy * cancer * on cytostatic treatment.

Keywords: speckle tracking 2d echocardiography left ventricle residual function pci, percutaneous coronary intervention single coronary artery multiple coronary arteries
impact of hmgb1 on diastolic dysfunction in hypertensive patients

Conditions: Diastolic Dysfunction; Hypertension; Inflammation

Summary: this study evaluated the association between hmgb1 and diastolic dysfunction in hypertensive patients. hmgb1 level were tested in all patients, and diastolic function determined by echocardiographic.


Eligibility criteria:
inclusion criteria: all of the hypertensive patients in both diastolic dysfunction and control groups were either newly diagnosed or were aware of hypertension without using any pharmacotherapy. - exclusion criteria: individuals already under treatment for hypertension were not include. -

Keywords: diastolic dysfunction hypertension hmgb1
systemic chemotherapy, lenvatinib plus sintilimab for icc with distant metastasis

Conditions: ICC

Summary: this study were designed to verify the better method of survival for icc with distant metastasis. since the traditional method for icc with distant metastasis. was gemox(first-line treatment from nccn guideline), our previous study found similar results from folfox (second-line treatment from nccn guideline) compared with gemox. our current study were conducted for further investigation to verify the better method for with distant metastasis.

icc (intrahepatic cholangiocarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. treatment methods was few and far from satisfaction. the treatment recommended from nccn guideline was gemox (systemic chemotheray) and clinical trials. our previous study has demonstrate folfox (systemic chemotheray based on oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with gemox. further study was needed to intensive confirmation of the result. we designed this study to demonstrate the hypothesis. metastasis iccs were recruited and screened by our criteria. all patients were treated with folfox (systemic chemotheray based on oxaliplatin#5-fluorouracil ), lenvatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of pd-1 antibody).

Eligibility criteria:
inclusion criteria: * the diagnosis of intrahepatic cholangiocarcinoma (icc) * with distant metastasis * patients must have at least one tumor lesion that can be accurately measured according to mrecist criteria. * with no previous treatment * no cirrhosis or cirrhotic status of child-pugh class a only * not amendable to surgical resection ,local ablative therapy and any other cured treatment * the following laboratory parameters: platelet count ≥ 60,000/μl hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/ l serum albumin ≥ 32 g/l asl and ast ≤ 6 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.

Keywords: icc lenvatinib sintilimab systemic chemotheray
a 10-week study evaluating the efficacy and safety of pd 0332334 in patients with generalized anxiety disorder (1)

Conditions: Generalized Anxiety Disorder

Summary: this is a 10-week trial that evaluates the efficacy and safety of pd 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.

termination reason: on february 23rd 2009, a decision to terminate further development for pd 0332334 was communicated to investigators in this study. the decision to terminate this study was not based on any safety concerns.

Eligibility criteria:
inclusion criteria: * diagnosis of gad (diagnostic and statistical manual iv \[dsm iv\], 300.02) as established by the clinician (psychiatrist or licensed clinical psychologist) who has interviewed the subject using all sources of data including the mini international neuropsychiatric interview (mini) for dsm iv axis i disorders and other clinical information. subjects with specific phobia(s) (as defined in dsm iv) or dysthymic disorder will be allowed in the study. * subjects must have a ham a total score ≥20 at the screening (v1) and randomization (v2) visits. subjects must also have a covi anxiety scale score of ≥9 and a raskin depression scale score ≤7 at the screening (v1) visit to ensure predominance of anxiety symptoms over depression symptoms. exclusion criteria: * subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, neurologic, active infections, immunological, or allergic disease (including drug allergies). * any of the following current (within the past 6 months through the present) dsm-iv axis i diagnosis: major depressive disorder, obsessive compulsive disorder, panic disorder, agoraphobia, posttraumatic stress disorder, anorexia, bulimia, caffeine induced anxiety disorder, alcohol or substance abuse or dependence unless in full remission for at least 6 months, social anxiety disorder. * any of the following past or current dsm-iv axis i diagnoses: schizophrenia, psychotic disorder, delirium, dementia, amnestic, and other clinically significant cognitive disorders, bipolar or schizoaffective disorder, cyclothymic disorder, dissociative disorders. * antisocial or borderline personality disorder. * serious suicidal risk per the clinical investigator's judgment.

Keywords: pd 0332334 phase 3 pivotal trial
famotidine in covid-19 intensive care unit

Conditions: COVID-19 Pandemic

Summary: the covid-19 disease, caused by sars-cov-2 virus, started in december 2019 and created a pandemic with high mortality and morbidity. since a fully proven treatment has not been developed, the efficacy of currently available treatments is being investigated. famotidine, an h2receptor blocker, is one of the drug treatments being investigated. in this study, we aimed to investigate the effect of famotidine treatment on the clinic and mortality of covid-19 patients treated in the intensive care unit.

the computer and written records of the patients followed in the covid-19 intensive care units of a research hospital during the pandemic process will be examined. patients over the age of 18 who have sars-cov-2 mrna detected by nasopharyngeal pcr (polymeraze chaine reaction) will be included in the study. patients with immunosuppression, end-stage renal disease, liver disease, g6pd deficiency, alt/ast \>5, long qt syndrome in ecg, diagnosed with psoriasis, porphyria, pregnant, and allergic reactions to famotidine or similar drugs were excluded from the study. patients' age, gender, comorbidities, smoking and apache ii score will be recorded. patients who were administered famotidine 160 mg/day po or nasogastric and were not given this treatment since their admission to the intensive care unit will be compared. the primary outcome will be the need for invasive mechanical ventilation, intensive care mortality, and both. as a secondary outcome, serum markers indicating the severity of the disease (leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, crp, d-dimer, fibrinogen, procalcitonin, il-6, troponin, creatinine, ast, alt, p/f ratio and lactate) will be recorded.

Eligibility criteria:
inclusion criteria: * patients who have sars-cov-2 mrna detected by nasopharyngeal pcr exclusion criteria: * immunosuppression * end-stage renal disease * liver disease * g6pd deficiency * long qt syndrome in ecg * psoriasis * porphyria * pregnant * allergic reactions to famotidine or similar drugs

Keywords: covid-19 intensive care unit famotidine mortality entubation
compassionate use of brontictuzumab for adenoid cystic carcinoma (acc)

Conditions: Adenoid Cystic Carcinoma

Summary: the goal of this study is to start treatment with the notch1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. the therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (acc) with notch 1 mutations. this is considered an investigational treatment.

treatment: participant will receive brontictuzumab by vein over 30 minutes one time every 3 weeks. clinic visits: on day 1 of cycle 1 and then every 3 weeks from then on: * participant will have a physical exam * blood (about 3 teaspoons) will be drawn for routine tests. every 6 weeks, participant will have an mri and ct scan to check the status of the disease. length of treatment: participant may continue taking brontictuzumab for as long as the doctor thinks it is in their best interest. participant will no longer be able to take the drug if the disease gets worse, they develop another illness that prevents receiving more treatment, or if intolerable side effects occur. brontictuzumab is not fda approved or commercially available. it is currently being used for research purposes only.

Eligibility criteria:
inclusion criteria: 1. eastern cooperative oncology group (ecog) performance status 0 to 1 2. organ and marrow function as follows: absolute neutrophil count (anc) ≥1000/mm3, platelets ≥50,000/dl, hemoglobin ≥8 g/dl, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dl or creatinine clearance ≥50 ml/min, alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 3 times the upper limit of normal. 3. central nervous system (cns) metastases allowed if subject does not require steroids, brain metastases are clinically stable without symptomatic progression 4. capability to understand and comply with the protocol and signed informed consent document. exclusion criteria: 1. major medical conditions that might affect study participation (e.g. uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease) 2. inability or unwillingness to abide by the study protocol or cooperate fully with the investigator.

Keywords: brontictuzumab
clinical comparison of two daily disposable soft contact lenses

Conditions: Myopia; Refractive Errors

Summary: the purpose of this study is to evaluate the overall performance of investigational contact lenses (dd t2) when compared to clariti® 1 day contact lenses.


Eligibility criteria:
inclusion criteria: * understand and sign an informed consent form; * successful wear of daily disposable spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months; * best-corrected visual acuity (bcva) 20/25 or better in each eye; * willing to stop wearing habitual contact lenses for the duration of study participation; * other protocol-specified inclusion criteria may apply. exclusion criteria: * anterior segment infection, inflammation, or abnormality or disease that contraindicates contact lens wear, as determined by the investigator; * use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; * refractive, ocular, or intraocular surgery, as specified in the protocol; * eye condition or injury, as specified in the protocol; * current or history of intolerance, hypersensitivity, or allergy to any component of the study products; * wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment; * use of topical ocular medications and artificial tear or rewetting drops requiring instillation during contact lens wear; * currently wearing clariti® 1 day contact lenses; * habitually wearing monovision or multifocal lenses during the last 3 months; * other protocol-specified exclusion criteria may apply.

Keywords: soft contact lenses vision eyesight
examining the impact of an online, non-restrictive diet among persons with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the current study aims to test an online, non-restrictive diet among persons with multiple sclerosis (ms). diet is the number one searched second-line therapy among persons with ms, however there are currently no established dietary approaches to improve health and wellbeing among persons with ms. participants will complete the 8-week diet program using an online application. the primary research question is whether the diet program is acceptable and can improve general health indicators including cholesterol, glucose, body weight, body fat as well as ms symptoms (i.e., walking, cognition, fatigue, and quality of life).


Eligibility criteria:
inclusion criteria: * age 18-70 years * a self-reported diagnosis of multiple sclerosis * relapse free in past 30 days * non-pregnant * willing and able to visit university of north texas on two testing occasions exclusion criteria: * electronic medical implant, such as a heart pacemaker or an implantable cardioverter defibrillator (icd)
effect of coccinia cordifolia extract on blood sugar of newly diagnosed diabetics

Conditions: Diabetes

Summary: the purpose of the study was to evaluate the effectiveness of coccinia cordifolia (synonym coccinia indica) on the blood glucose levels of newly detected type 2 diabetic patients requiring only behavioral or lifestyle intervention. the hypothesis of the study is that there will be significant decrease in the blood glucose levels after a period of 90 days in the diabetic patients who consumed the coccinia extract.

the prevalence of diabetes is increasing in all countries, especially india at an alarming rate. appropriate interventions in the form of weight reduction, changes in dietary habits and increased physical activity could help in preventing or delaying the onset of diabetes and reducing the burden due to non communicable diseases in india. plants or their extracts may also have a potential therapeutic role in the treatment for diabetes. coccinia indica (synonym coccinia cordifolia), a herb that belongs to the cucurbitaceae family and that grows abundantly in india, is widely used in the traditional treatment of diabetes mellitus. coccinia leaves, when administered orally twice a day for six weeks, to patients with untreated but uncomplicated maturity onset diabetes demonstrated hypoglycemic activity with significant improvement in glucose tolerance. the aim of the present study was to evaluate the effectiveness of coccinia cordifolia on the blood glucose levels of newly detected type 2 diabetic patients requiring only behavioral or lifestyle intervention. the study was a double blind, placebo controlled, randomized trial. the study was carried out at nutrition and lifestyle management clinic, st. john's medical college hospital. after recruitment , the diabetic subjects were assigned either to the experimental or placebo group. they were provided with the extract for a period of 90 days. prior to the intervention, the subjects underwent baseline investigations which included anthropometric, biochemical, dietary and physical activity assessment. these investigations were repeated at day 45 and day 90 of the study. the compliance of the subjects to the ingestion of capsules was documented every week when they reported to the nutrition clinic. all the study subjects were provided with standard dietary and physical activity advice for the control of their blood sugars. the compliance of the subjects to the prescribed diet and physical activity was assessed weekly by asking the subjects to rate their compliance on a scale of 0-100%.

Eligibility criteria:
inclusion criteria: 1. patients with clinical diagnosis of type 2 diabetes requiring only behavioral or lifestyle intervention. 2. fasting blood glucose in the range of 110-180 mg/dl 3. age range - 35 to 60 years 4. willing to participate in the study and perform all measurements exclusion criteria: 1. presence of any chronic disease or organ failure 2. concurrent use of medication to control blood glucose levels

Keywords: diabetes india coccinia cordifolia coccinia indica blood glucose levels
freeze cohort study

Conditions: Arrhythmia

Summary: safety and efficacy in radiofrequency (rf) or cryoballoon atrial fibrillation (af) ablation will be investigated in a cohort study design in experienced electrophysiologic (ep) centers analyzing propensity-matched cohorts.

prior to participation in the cohort-study each ep center had to perform a minimum of 50 rf or 50 cryoballoon approaches. to insure the consecutiveness of recruitment, participating centers have to announce the intention to ablate the patient prior to the procedure to the coordinating center in ludwigshafen. after inclusion of 500 patients with well accepted criteria for af ablation undergoing cryoballoon pulmonary vein isolation (pvi) in experienced german ep centers inclusion of patients will be extended to european centers. a total of 4.000 patients will be included in the cohort-study, 2.000 in both the cryoballoon and the rf arm.

Eligibility criteria:
inclusion criteria: * documented paroxysmal af (2 episodes of paf within the last 3 months) or persistent af (lasting \< 1 year) * first ablation of af * age ≥18 years * documented inefficacy of at least 1 aad not including β-blockers * written informed consent exclusion criteria: * longstanding persistent af lasting \> 1 year * acute coronary syndrome (acs) * heart failure nyha iv * thrombocytosis, thrombocytopenia * any condition contraindicating chronic anticoagulation * stroke or tia within 6 months prior to ablation * uncontrolled hyperthyroidism * pregnancy * life expectancy \< 1 year

Keywords: cardiac arrhythmia catheter ablation cohort study cryoballoon radiofrequency